All In Biotech

NDA 213135 · Azurity

Sutab

Magnesium Sulfate, Potassium Chloride, Sodium Sulfate · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Nov 10, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 1 recruiting

FAERS reports

1,589

211 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUTAB is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SUTAB · MAGNESIUM SULFATE 0.225GM; POTASSIUM CHLORIDE 0.188GM; SODIUM SULFATE 1.479GM · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sutab" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting827
  • nausea424
  • drug ineffective141
  • abdominal distension94
  • headache94
  • abdominal pain upper88
  • pruritus66
  • wrong technique in product usage process65
  • abdominal pain63
  • dizziness62
  • tremor61
  • chills56

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20202
2021263
2022438
2023426
202446
2025397
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sutab (Sod Sulf/Pot Chloride/Mag Sulf)

2024 spending

$25.4M

Beneficiaries

152,205

156,816 claims

Per beneficiary

$167

$6.74 per unit

View as table
YearSpending
2020$0
2021$9,897,287
2022$20,354,859
2023$29,113,137
2024$25,360,554

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.